News | September 08, 2008

MicroMed Cardiovascular Purchased, Taken Private by SynCardia CEO, Investors

September 9, 2008 - Ventricular assist device manufacturer MicroMed Cardiovascular Inc. today said it completed all necessary steps and is now a private company.

The final step in the process was a reverse split of its common stock and a repurchase of the fractional shares from the MicroMed shareholders holding smaller positions. At the time of the reverse split, E-Wilson LLC had accumulated 97.5 percent of the outstanding MicroMed shares. MicroMed received confirmation of the reverse split on Aug. 25, 2008, making E-Wilson the single shareholder of MicroMed.

On Feb. 1, 2008, MicroMed entered into a credit agreement with E-Wilson, under which E-Wilson agreed to provide up to $10 million in financing in a series of advances over the next two years, subject to certain conditions.

E-Wilson was formed by Rodger Ford, shareholder and CEO of SynCardia Systems and David Mackstaller, shareholder and vice president of development of SynCardia Systems, as a special purpose entity to own MicroMed shares. While MicroMed and SynCardia have some common shareholders, they are separate and operate as two independent entities.

MicroMed is a pioneer in the accelerating field of mechanical circulatory support and manufactures a small implantable ventricular assist device, the DeBakey VAD, which is intended to increase the cardiac output of a patient with a failing left ventricle. The DeBakey VAD and its related technology were developed in a partnership with NASA. In 1998, the DeBakey VAD became the first device of its kind to be used in humans. It weighs 92 grams and is implanted in the pericardial space.

The DeBakey VAD recently received approval for two upgrades, now approved in Europe with a CE mark and in the U.S. pediatric VAD under a humanitarian device exemption. A bridge to transplant clinical study is underway in the U.S. under an IDE that may eventually lead to a PMA.

The modern DeBakey VAD is the HeartAssist 5. It has a direct flow measurement system intended to provide blood flow data 24/7. The HeartAssist 5 and its earlier DeBakey VAD version have been implanted more than 440 times worldwide.

The HeartAssist 5 Adult VAD is an investigational device, limited by U.S. law to investigational use.

The HeartAssist 5 Pediatric VAD is authorized by federal law for use in providing temporary mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients 5-16 years old who are listed for transplant. The effectiveness of this device for this use has not been demonstrated.

For more information:

Related Content

Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Abiomed Impella CP pVAD, third-generation CP
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — Abiomed Inc.
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Overlay Init